Related Experiment Video
Updated: May 12, 2025
A Reliable Porcine Fascio-Cutaneous Flap Model for Vascularized Composite Allografts Bioengineering Studies
Published on: March 31, 2022
Donor Site Morbidity of the Medial Sural Artery Perforator (MSAP) Free Flap for Head & Neck Reconstruction
Lillian W Dattilo1, Emilie C M de Groot1, Sarah Nyirjesy1
1Department of Otolaryngology-Head and Neck Surgery, Harvard Medical School, Massachusetts Eye & Ear, Boston, Massachusetts, USA.
Background:
Minimal donor site morbidity is often cited as one of the main advantages of the medial sural artery perforator (MSAP) free flap; however, few studies have examined functional outcomes.
Methods:
This retrospective cohort study analyzed patients undergoing MSAP for head and neck reconstruction from 2022 to 2024. A modified lower extremity functional scale (LEFS), with 80 being a maximum score, was administered to assess functional morbidity.
Results:
Twenty two patients underwent successful MSAP flap. At < 1 month after surgery, the average LEFS was 56.0 (95% CI, 43.8-68.2). At 1-3 months, the average score was 63.0 (95% CI, 56.0-70.0); at 3-6 months, it was 75.0 (95% CI, 70.0-80.0), and at 6-12 months, it was 78.1 (95% CI, 75.4-80.0). Beyond 12 months, the average score was 79.8 (95% CI, 79.8-80.0).
Conclusions And Relevance:
The MSAP free flap is an excellent free tissue option for head & neck reconstruction with minimal donor site morbidity.
